Astromech Buys Form Bio for $230 Million to Fuse Evolutionary AI With Gene Design
Astromech's $230 million all-stock acquisition of Form Bio pairs an in-development evolutionary AI with gene-design tools that lifted AAV full-genome content from 13% to 59%.

Why it matters
- Astromech acquired Form Bio on November 17, 2026 in an all-stock deal valued at $230 million.
- Form Bio's promoter and nuclease work raised AAV full-genome content from 13% to 59% in one month in a Duchenne muscular dystrophy candidate.
- Coding-sequence optimization alone lifted full-genome content from about 2% to about 45% in a separate program.
- Form Bio raised more than $40 million and Astromech more than $60 million; both spun out of Colossal Biosciences.
- Andrew Busey, Form Bio co-founder and former CEO, becomes Astromech's Chief AI Officer and Head of Technology.
Astromech has acquired genetic-medicine design company Form Bio in an all-stock deal worth $230 million, the company announced on November 17, 2026. The purchase adds Form Bio's intellectual property, selected contracts and assets, and its team to Astromech's evolutionary modeling operation.
The deal's logic is straightforward. Astromech builds evolutionary AI. Form Bio builds tools for designing genetic medicines, optimizing gene-therapy vectors and manufacturing, and assessing genomic quality. The combined company wants researchers to move from identifying evolutionary patterns to designing and testing genetic constructs across human therapeutics, genome engineering and animal health.
The stakes are real. Gene-therapy manufacturing still fights quality problems that drive up cost and slow regulatory approval. If evolutionary insight can catch those problems at the design stage, the savings compound across the entire development pipeline.
Who is joining whom?
Form Bio co-founder and former CEO Andrew Busey becomes Astromech's Chief AI Officer and Head of Technology. He framed the deal as a continuation of Form Bio's own arc, from computational work on de-extinction to foundation models for designing human therapeutics.
"Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make," Busey said.
Both companies share a lineage. Form Bio was developed inside Colossal Biosciences and launched as a spinout in September 2022, later expanding from multi-species genome engineering into human genetic medicines. Astromech grew out of Colossal's comparative-genomics, ancient-DNA and computational-biology work, and was co-founded by George Church and Ben Lamm. Form Bio had raised more than $40 million in venture financing; Astromech had raised more than $60 million.
What does Astromech's AI actually do?
Astromech's own technical description is candid about maturity. Its Large Life Model remains a system in development. It is designed to learn across species and evolutionary time, combining attention-based deep learning with Bayesian reconstruction of ancestral sequences and regulatory states. The listed architecture includes:
- A graph-based pangenome that captures structural genetic variants across populations
- A multi-omics integrator, also in development, meant to unify biological insight across complex systems
Form Bio's side of the ledger is more concrete. Its product materials describe:
- FormSightAI, which screens thousands of vector designs in silico to find candidates intended to improve yield and reduce contaminants
- FormManufacturing, which supports work from design through commercial release
- FormBatchQC, which provides lot-level analysis of contaminants and comparability
The companies' stated aim is to address quality challenges earlier, reducing unwanted components during design and potentially cutting the need for downstream purification.
What results has Form Bio already reported?
The strongest number in the deal materials comes from a partnership Form Bio announced on October 6, 2025 with Cure Rare Disease. Promoter modification and nuclease optimization raised AAV full-genome content in a Duchenne muscular dystrophy candidate from 13% to 59% within one month. The work combined long-read sequencing, genome-integrity analysis, rational design, and AI and machine-learning models.
Full-genome content measures the proportion of capsids containing a complete vector genome, and it is a critical quality attribute for regulatory approval. Cure Rare Disease said the work advanced the program to preclinical studies in living organisms. The result concerns vector-manufacturing quality and preclinical progress, not clinical outcomes in patients.
The acquisition announcement adds a second data point. In a separate program, coding-sequence optimization alone increased full-genome content from about 2% to about 45%, with expression held at baseline. The two examples used different design levers: the Duchenne work changed the promoter and nuclease, while the other changed only the coding sequence.
Form Bio's tools already support genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences, according to the acquisition announcement.
Can evolutionary AI improve on proven tools?
That is the open technical question. The acquisition places Form Bio's applied design tools and external program experience next to an evolutionary-AI system that is still under construction. Form Bio's reported gains came from design and manufacturing levers that already work today.
The bet is that Astromech's evolutionary reconstruction, once finished, adds measurable improvements to construct-design and manufacturing results Form Bio already delivers. Until the Large Life Model ships and shows gains on top of numbers like 13%-to-59%, the $230 million price rests largely on Form Bio's track record and the promise that evolutionary insight can sharpen it.
By Elena Vasquez
Source: unite.ai
More from Elena Vasquez
Show full bio
Market editor covering technology and product news in artificial intelligence and machine learning at AI In Context.
708 articles
Related articles
- Science Corporation Raises $400M Series D to Scale PRIMA Retinal Implant
- Isomorphic Labs raises $5B to push AI-designed drugs into trials
- Anthropic Says Claude Autonomously Discovered a Crispr-Like Enzyme System
- Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test
- Basecamp Research raised $140M to turn evolution into AI training data